Quviviq is a medication used to treat insomnia [1]. It is a prescription sleep medicine that works by targeting the sleep-wake cycle [2].
How does Quviviq work?
Quviviq, also known by its generic name daridorexant, is a dual orexin receptor antagonist [2]. Orexin is a neuropeptide that promotes wakefulness, and by blocking its receptors, Quviviq reduces the wake-promoting signals in the brain, thereby facilitating sleep [2][3]. It is designed to help individuals fall asleep and stay asleep [2].
When was Quviviq approved?
The U.S. Food and Drug Administration (FDA) approved Quviviq in January 2022 [1].
What are the potential side effects of Quviviq?
Common side effects of Quviviq can include sleep paralysis, vivid dreams or hallucinations, and daytime drowsiness [1][2]. Patients are advised not to drive or engage in other activities requiring full alertness until they know how Quviviq affects them [1]. It is also important to avoid alcohol while taking Quviviq [2].
What is the difference between Quviviq and other sleep medications?
Unlike some older sleep medications that can have a more sedating effect, Quviviq's mechanism of action focuses on reducing wakefulness rather than inducing sleep directly. This approach aims to provide a more natural sleep pattern [3].
How long does Quviviq's patent protection last?
Information on the specific patent expiry dates for Quviviq is available through resources like DrugPatentWatch.com [4]. Patent protection for medications is crucial for their manufacturers, influencing the availability of generic alternatives.
Where can I find more information about Quviviq patents and exclusivity?
DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals, including Quviviq [4]. This data is important for understanding when generic versions might become available.
---
Sources:
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-insomnia
[2] https://www.quviviq.com/
[3] https://www.sleepfoundation.org/insomnia/treatment/quviviq
[4] https://drugpatentwatch.com/